Sabbin Sakamako a cikin Marasa lafiya da ke fama da Ciwon daji na Nono da ke fama da Karancin Libido

A KYAUTA Kyauta 5 | eTurboNews | eTN
Avatar na Linda Hohnholz
Written by Linda Hohnholz

Sabon bincike daga Memorial Sloan Kettering Cancer Center (MSK) wanda masanin ilimin likitancin likita Shari Goldfarb, MD, da abokan aiki suka jagoranta, sun ba da rahoton sakamako mai kyau don amfani da allunan Addyi (flibanserin) a cikin marasa lafiya da ciwon nono akan maganin endocrin da ke fama da jiyya- ko cuta. - jawo low libido. A halin yanzu akwai rashin ingantaccen hanyoyin magani ga waɗannan matan da ke fama da matsalar sha'awar jima'i (HSDD), ko asarar sha'awar jima'i, kuma an kiyasta cewa fiye da mutane miliyan 16.5 suna rayuwa tare da fiye da maganin ciwon daji a Amurka. An gabatar da sakamakon binciken a taron shekara-shekara don Ƙungiyar Ƙasa ta Duniya don Nazarin Lafiyar Jima'i (ISSWSH).

Dokta Shari Goldfarb, kwararriyar likitancin nono daga Cibiyar Memorial Sloan Kettering Cancer Center kuma mai binciken farko na binciken ya ce, “Lalacewar jima’i na daya daga cikin illolin da ake samu kuma ba a magance matsalar jiyya a tsakanin mata da suka tsira daga cutar kansa ba. A matsayin masu bincike, muna so mu gudanar da bincike don taimakawa wajen magance raguwar libido, wanda sau da yawa alama ce ta damuwa ga mata akan maganin endocrin. Wannan binciken ya kimanta tasirin flibanserin akan rage libido a cikin mata masu ciwon nono akan maganin endocrin. Sakamakon farko yana da ban sha'awa kuma ya nuna cewa wannan binciken yana kan hanya don saduwa da ƙayyadaddun yuwuwar ƙarshensa tare da yawancin mahalarta binciken suna nuna fa'ida daga flibanserin."

Wannan binciken da ke gudana zai shigar da mata 30 da ciwon nono akan maganin endocrin da ke fama da HSDD. Sakamakon farko daga mata 20 na farko da suka kammala makonni 24 na maganin flibanserin sun nuna cewa binciken yana kan hanya don saduwa da matakin ƙarshe na farkonsa, tare da> 70% na mata sun kammala lokacin jiyya na makonni 24 da 15% sun daina binciken da wuri saboda m aukuwa, duk abin da ya faru a lokacin farkon makonni biyu na jiyya. Abubuwan da ba su da kyau sun haɗa da dizziness, rashin barci, barci, da tashin hankali. Babu wani mugun abu da ya faru a cikin binciken. Bugu da ƙari, yawancin mata sun ba da rahoton karuwar sha'awar jima'i, yawan adadin abubuwan da suka faru na jima'i (SSEs) da kuma rage yawan damuwa bayan makonni 8 na jiyya.

Cindy Eckert, Shugaba na Sprout Pharmaceuticals ta ce, "Zuciyata tana tafiya ga masu tsira da ciwon nono waɗanda galibi suna fama da ƙarancin sha'awarsu. Waɗannan sakamakon wucin gadi akan amfani da flibanserin a cikin wannan yawan suna ƙarfafawa. Muna godiya ga Dr. Goldfarb da Sloan Kettering don ɗaukar wannan bincike mai zurfi tare da raba shi tare da ƙungiyar likitocin. "

Har zuwa wannan batu, babu magungunan FDA da aka amince da ita ga mata masu HSDD na biyu na ciwon daji ko maganinta, kuma wani binciken da aka buga kwanan nan na Phase II ya gano cewa bupropion bai fi tasiri ba fiye da placebo wajen inganta sha'awar jima'i a cikin mata masu tsira da ciwon daji. Amma duk da haka, an kiyasta cewa kashi 70 cikin 2018 na matan da aka gano suna da ciwon nono suna ba da rahoton rashin aikin jima'i; wannan ya haɗa da rikice-rikice na sha'awar jima'i da amsa jima'i. A cikin feb XNUMX, jama'ar ASCO na Amurka na ASCO) sun buga jagororin da ke ba da shawarar "ga mata masu fama da rashin kulawa da / ko kuma inabi. Ga matan da suka riga sun yi mazan jiya tare da HSDD, likitoci na iya ba da shawarar flibanserin." Ka'idojin sun kuma bayyana cewa "kwamitin ya lura cewa ba a gwada flibanserin a cikin mata masu tarihin ciwon daji ko kuma matan da ke shan maganin hormonal ba, don haka hadarin / fa'idar wannan maganin ga matan da aka gano suna da ciwon daji ba a sani ba." Binciken binciken Dr. Goldfarb ya ba da sababbin bayanai don taimakawa wajen rufe wannan gibi a ilimin likitanci.

Game da marubucin

Avatar na Linda Hohnholz

Linda Hohnholz

Edita a shugaba don eTurboNews bisa ga eTN HQ.

Labarai
Sanarwa na
bako
0 comments
Bayanin Cikin Lissafi
Duba duk maganganu
0
Za a son tunanin ku, don Allah sharhi.x
()
x
Share zuwa...